Modeling the pharmacodynamics of highly schedule-dependent agents: Exemplified by cytarabine-based regimens in acute myeloid leukemia

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7415-7425

  Braess, Jan ^a   Fiegl, Michael ^a   Lorenz, Isolde ^a   Waxenberger, Karin ^a   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MAFOSFAMIDE; MITOXANTRONE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BONE MARROW CELLS; CELL SURVIVAL; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOID; META-ANALYSIS; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS;

EID: 27144516782     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0360     Document Type: Article

References (55)

1. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group, Blood 1999;12:4116-24.
2. Bishop JF, Matthews JP, Young G A, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;5:1710-7.
3. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;8:1924-30.
4. Kern W, Schoch C, Haferlach T, et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000;2:226-31.
5. Field SB, Raaphorst GP. Thermal dose. In: Field SB, Hand JW, editors. An introduction to the practical aspects of clinical hyperthermia. London: Taylor and Francis; 1990. p. 10-54.
6. Schiller G, Gajewski J, Nimer S, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992;2:170-7.
7. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;8:2841-51.
8. Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res 1989;23:6615-20.
9. Levasseur LM, Slocum HK, Rustum YM, Greco WR. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 1998;24:5749-61.
10. Millenbaugh NJ, Wientjes MG, Au JL. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 2000;4:265-72.
11. SOFTmax PRO: user manual. Version 2.4. Sunnyvale (California): Molecular Devices Corp.; 1998.
12. Calvert AH, Lind MJ, Ghazal-Aswad S, et al. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. Semin Oncol 1994;5 Suppl 12:1-6.
13. Takashima Y, Matsuyama K. Pharmacokinetic studies of intermediate- to high-dose 1-β-D-arabinofuranosyl-cytosine in children with acute leukemia and lymphoma. J Clin Pharmacol 1987;4:330-3.
14. Spriggs DR, Sokal JE, Griffin J, Kufe DW. Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. Cancer Drug Deliv 1986;3:211-6.
15. Schleyer E. Zum Stellenwert pharmakokinetischer Untersuchungen in der Therapie maligner Erkrankungen am Beispiel zweier Antimetaboliten, Cytosin-Arabinosid und Cytarabine-Ocfosfate (YNK01) [State doctorate]. Dresden: Gustav-Carus University; 1999.
16. Hiddemann W, Schleyer E, Uhrmeister C, et al. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: preliminary clinical and pharmacological data of a randomized comparison. Cancer Treat Rev 1990;2-3:279-85.
17. Kreis W, Chaudhri F, Chan K, et al. Pharmacokinetics of low-dose 1-β-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Cancer Res 1985;12 Pt 1:6498-501.
18. Burk M, Heyll A, Arning M, Volmer M, Fartash K, Schneider W. Pharmacokinetics of high-dose cytarabine and its deamination product: a reappraisal. Leuk Lymphoma 1997;27:321-7.
19. Arlin Z, Case DC, Jr., Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;3:177-83.
20. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990;1:27-32.
21. Buchner T, Hiddemann W, Blasius S, et al. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. Hematol Blood Transfus 1990;261-6.
22. Cassileth PA, Andersen JW, Bennett JM, et al. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 1992;6:116-9.
23. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;10:2520-6.
24. Elonen E, Almqvist A, Hanninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 1998;7:1041-8.
25. Fopp M, Fey MF, Bacchi M, et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1997;3:251-7.
26. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 1991;6:510-6.
27. Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995;1:3-9.
28. Jehn U. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities. Leuk Lymphoma 1994;1-2:99-112.
29. Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;1:204-13.
30. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;3:872-81.
31. Mandelli F, Vegna ML, Avvisati G, et al. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. Ann Hematol 1992;4:166-72.
32. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;14:896-903.
33. Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 1994;1:11-5.
34. Pignon B, Witz F, Desablens B, et al. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicine is more effective than zorubicine for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group. Br J Haematol 1996;2:333-41.
35. Reiffers J, Huguet F, Stoppa AM, et al. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996;3:389-95.
36. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;2:457-62.
37. Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003;4:1202-10. Epub 2003 Mar 27.
38. Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res 1990;10:895-903.
39. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;2:272-9.
40. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992;7:1103-11.
41. Wiernik PH, Banks PL, Case DC, Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;2:313-9.
42. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;8:743-52.
43. Plunkett W, Liliemark JO, Estey E, Keating M. Saturation of ara-CTP formation during high-dose ara-c therapy: pharmacological rationale for intermediate-dose ara-c. Semin Oncol 1987;2:159-66.
44. GandhiV, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;1:116-24.
45. Estey E, Keating M, McCredie K, Freireich EJ, Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990;2:95-9.
46. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ. Variables predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;8:580-3.
47. Wurthwein G, Boos J. Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature. Anticancer Drugs 2001;2:151-8.
48. Wurthwein G, Boos J. Low dose-high dose: what is the right dose? Pharmacokinetic modeling of etoposide. Cancer Chemother Pharmacol 2002;4:303-8. Epub 2002 Jan 30.
49. Tallman MS. Relevance of pathological classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice. Cancer Treat Res 2004;45-67.
50. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or T(16;16)(p13;q23): results from CALGB 8461. J Clin Oncol 2004;6:1087-94.
51. Byrd JC, Dodge RK, Carroll AJ, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles high-dose cytarabine are administered. J Clin Oncol 1999;12:3767-75.
52. Schoch C, Haferlach T, Haase D, et al. Patients with de-novo acute myeloid leukemia and complex karyotype aberrations have a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;1:118-26.
53. Spriggs D, Robbins G, Arthur K, Mayer RF, Kufe D. Prolonged high dose ARA-C infusions in acute leukemia. Leukemia 1988;5:304-6.
54. Stone RM, Spriggs D, Dhawan RK, Arthur KA, Mayer RJ, Kufe D. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia 1990;12:843-7.
55. Grant S, Baker M, Bhalla K. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2′-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Leukemia 1993;12:1933-8.